�ݺ�ߣshows by User: young651

�ݺ�ߣshows by User: young651 / http://www.slideshare.net/images/logo.gif �ݺ�ߣshows by User: young651 / Wed, 15 Mar 2017 15:50:14 GMT �ݺ�ߣShare feed for �ݺ�ߣshows by User: young651 Nicholas Young, CV, research scientist, immunology and rheumatology /slideshow/nicholas-young-cv-research-scientist-immunology-and-rheumatology/73179048 n-170315155014
Resume/CV for Nicholas Young; research scientist at The Ohio State University Wexner Medical Center in the Division of Rheumatology and Immunology]]>
Resume/CV for Nicholas Young; research scientist at The Ohio State University Wexner Medical Center in the Division of Rheumatology and Immunology]]> Wed, 15 Mar 2017 15:50:14 GMT /slideshow/nicholas-young-cv-research-scientist-immunology-and-rheumatology/73179048 young651@slideshare.net(young651) Nicholas Young, CV, research scientist, immunology and rheumatology young651 Resume/CV for Nicholas Young; research scientist at The Ohio State University Wexner Medical Center in the Division of Rheumatology and Immunology <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/n-170315155014-thumbnail.jpg?width=120&height=120&fit=bounds" /> Resume/CV for Nicholas Young; research scientist at The Ohio State University Wexner Medical Center in the Division of Rheumatology and Immunology

Nicholas Young, CV, research scientist, immunology and rheumatology from Nicholas Young

]]> 819 7 https://cdn.slidesharecdn.com/ss_thumbnails/n-170315155014-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 "Stress is Detrimental and Moderate Exercise is Beneficial to Lupus Nephritis Pathogenesis: Extra-Medicinal Influences on Chronic Autoimmune Inflammation" /slideshow/stress-is-detrimental-and-moderate-exercise-is-beneficial-to-lupus-nephritis-pathogenesis-extramedicinal-influences-on-chronic-autoimmune-inflammation/51862564 exercisepresentationsummaryedit-150820142357-lva1-app6892
Presented this work as a poster tour presentation at The European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology meeting June 10-13, 2015 in Rome, Italy. Awarded a travel bursary to attend this conference.]]>
Presented this work as a poster tour presentation at The European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology meeting June 10-13, 2015 in Rome, Italy. Awarded a travel bursary to attend this conference.]]> Thu, 20 Aug 2015 14:23:57 GMT /slideshow/stress-is-detrimental-and-moderate-exercise-is-beneficial-to-lupus-nephritis-pathogenesis-extramedicinal-influences-on-chronic-autoimmune-inflammation/51862564 young651@slideshare.net(young651) "Stress is Detrimental and Moderate Exercise is Beneficial to Lupus Nephritis Pathogenesis: Extra-Medicinal Influences on Chronic Autoimmune Inflammation" young651 Presented this work as a poster tour presentation at The European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology meeting June 10-13, 2015 in Rome, Italy. Awarded a travel bursary to attend this conference. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/exercisepresentationsummaryedit-150820142357-lva1-app6892-thumbnail.jpg?width=120&height=120&fit=bounds" /> Presented this work as a poster tour presentation at The European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology meeting June 10-13, 2015 in Rome, Italy. Awarded a travel bursary to attend this conference.

"Stress is Detrimental and Moderate Exercise is Beneficial to Lupus Nephritis Pathogenesis: Extra-Medicinal Influences on Chronic Autoimmune Inflammation" from Nicholas Young

]]> 698 11 https://cdn.slidesharecdn.com/ss_thumbnails/exercisepresentationsummaryedit-150820142357-lva1-app6892-thumbnail.jpg?width=120&height=120&fit=bounds presentation 000000 http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 "Oral administration of nano-emulsion curcumin suppresses LPS-induced NFkB signaling in inflammation and inhibits macrophage migration" /slideshow/oral-administration-of-nanoemulsion-curcumin-suppresses-lpsinduced-nfkb-signaling-in-inflammation-and-inhibits-macrophage-migration/51860637 curcumin-150820134219-lva1-app6891
Sildes from a portion of my talk per invitation of the Physiology research group at aTyr Pharma June 1-3, 2014, San Diego, CA. Subsequently, this project has translated to a human clinical trial of this patented anti-inflammatory drug (nanoemulsified curcumin; patented through my collaboration with the Department of Pharmacology at Ohio State).]]>
Sildes from a portion of my talk per invitation of the Physiology research group at aTyr Pharma June 1-3, 2014, San Diego, CA. Subsequently, this project has translated to a human clinical trial of this patented anti-inflammatory drug (nanoemulsified curcumin; patented through my collaboration with the Department of Pharmacology at Ohio State).]]> Thu, 20 Aug 2015 13:42:19 GMT /slideshow/oral-administration-of-nanoemulsion-curcumin-suppresses-lpsinduced-nfkb-signaling-in-inflammation-and-inhibits-macrophage-migration/51860637 young651@slideshare.net(young651) "Oral administration of nano-emulsion curcumin suppresses LPS-induced NFkB signaling in inflammation and inhibits macrophage migration" young651 Sildes from a portion of my talk per invitation of the Physiology research group at aTyr Pharma June 1-3, 2014, San Diego, CA. Subsequently, this project has translated to a human clinical trial of this patented anti-inflammatory drug (nanoemulsified curcumin; patented through my collaboration with the Department of Pharmacology at Ohio State). <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/curcumin-150820134219-lva1-app6891-thumbnail.jpg?width=120&height=120&fit=bounds" /> Sildes from a portion of my talk per invitation of the Physiology research group at aTyr Pharma June 1-3, 2014, San Diego, CA. Subsequently, this project has translated to a human clinical trial of this patented anti-inflammatory drug (nanoemulsified curcumin; patented through my collaboration with the Department of Pharmacology at Ohio State).

"Oral administration of nano-emulsion curcumin suppresses LPS-induced NFkB signaling in inflammation and inhibits macrophage migration" from Nicholas Young

]]> 923 9 https://cdn.slidesharecdn.com/ss_thumbnails/curcumin-150820134219-lva1-app6891-thumbnail.jpg?width=120&height=120&fit=bounds presentation 000000 http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Aberrant muscle antigen exposure in mice is sufficient to cause myositis in a Treg cell-deficient milieu /slideshow/aberrant-muscle-antigen-exposure-in-mice-is-sufficient-to-cause-myositis-in-a-treg-celldeficient-milieu/51860516 11-9-2012myositispresentationpptx-todate-150820133836-lva1-app6891
My talk on muscle auto-antigens in myositis presented at the American College of Rheumatology 79th Meeting during the “Myositis and Myopathies: Novel Insights into Disease Pathogenesis” concurrent abstract oral presentation session. November 4, 2012 in Washington, D.C.]]>
My talk on muscle auto-antigens in myositis presented at the American College of Rheumatology 79th Meeting during the “Myositis and Myopathies: Novel Insights into Disease Pathogenesis” concurrent abstract oral presentation session. November 4, 2012 in Washington, D.C.]]> Thu, 20 Aug 2015 13:38:36 GMT /slideshow/aberrant-muscle-antigen-exposure-in-mice-is-sufficient-to-cause-myositis-in-a-treg-celldeficient-milieu/51860516 young651@slideshare.net(young651) Aberrant muscle antigen exposure in mice is sufficient to cause myositis in a Treg cell-deficient milieu young651 My talk on muscle auto-antigens in myositis presented at the American College of Rheumatology 79th Meeting during the “Myositis and Myopathies: Novel Insights into Disease Pathogenesis” concurrent abstract oral presentation session. November 4, 2012 in Washington, D.C. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/11-9-2012myositispresentationpptx-todate-150820133836-lva1-app6891-thumbnail.jpg?width=120&height=120&fit=bounds" /> My talk on muscle auto-antigens in myositis presented at the American College of Rheumatology 79th Meeting during the “Myositis and Myopathies: Novel Insights into Disease Pathogenesis” concurrent abstract oral presentation session. November 4, 2012 in Washington, D.C.

Aberrant muscle antigen exposure in mice is sufficient to cause myositis in a Treg cell-deficient milieu from Nicholas Young

]]> 587 9 https://cdn.slidesharecdn.com/ss_thumbnails/11-9-2012myositispresentationpptx-todate-150820133836-lva1-app6891-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 “A Chimeric Human-Mouse Model of Sjögren's Syndrome” /slideshow/a-chimeric-humanmouse-model-of-sjgrens-syndrome/51860293 6-7-2014focissjs-150820133241-lva1-app6891
My talk from The Federation of Clinical Immunology Societies (FOCIS) annual meeting June 24-28, 2014 in Chicago, IL: “A Chimeric Human-Mouse Model of Sjögren's Syndrome”. Recipient of a travel award given to selected abstracts to attend this conference. ]]>
My talk from The Federation of Clinical Immunology Societies (FOCIS) annual meeting June 24-28, 2014 in Chicago, IL: “A Chimeric Human-Mouse Model of Sjögren's Syndrome”. Recipient of a travel award given to selected abstracts to attend this conference. ]]> Thu, 20 Aug 2015 13:32:41 GMT /slideshow/a-chimeric-humanmouse-model-of-sjgrens-syndrome/51860293 young651@slideshare.net(young651) “A Chimeric Human-Mouse Model of Sjögren's Syndrome” young651 My talk from The Federation of Clinical Immunology Societies (FOCIS) annual meeting June 24-28, 2014 in Chicago, IL: “A Chimeric Human-Mouse Model of Sjögren's Syndrome”. Recipient of a travel award given to selected abstracts to attend this conference. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/6-7-2014focissjs-150820133241-lva1-app6891-thumbnail.jpg?width=120&height=120&fit=bounds" /> My talk from The Federation of Clinical Immunology Societies (FOCIS) annual meeting June 24-28, 2014 in Chicago, IL: “A Chimeric Human-Mouse Model of Sjögren's Syndrome”. Recipient of a travel award given to selected abstracts to attend this conference.

“A Chimeric Human-Mouse Model of Sjögren's Syndrome” from Nicholas Young

]]> 319 8 https://cdn.slidesharecdn.com/ss_thumbnails/6-7-2014focissjs-150820133241-lva1-app6891-thumbnail.jpg?width=120&height=120&fit=bounds presentation 000000 http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 "Bioluminescent Imaging of Histidyl-Transfer RNA Synthetase-Induced Myositis Reveals Early-Phase Involvement of NF-kB-Mediated Inflammation" /slideshow/bioluminescent-imaging-of-histidyltransfer-rna-synthetaseinduced-myositis-reveals-earlyphase-involvement-of-nfkbmediated-inflammation/51860205 11-7-2014presentation-final-edit-150820132945-lva1-app6891
My talk from the American College of Rheumatology Meeting in Boston, MA, November 14-19, 2014: • "Bioluminescent Imaging of Histidyl-Transfer RNA Synthetase-Induced Myositis Reveals Early-Phase Involvement of NF-kB-Mediated Inflammation".]]>
My talk from the American College of Rheumatology Meeting in Boston, MA, November 14-19, 2014: • "Bioluminescent Imaging of Histidyl-Transfer RNA Synthetase-Induced Myositis Reveals Early-Phase Involvement of NF-kB-Mediated Inflammation".]]> Thu, 20 Aug 2015 13:29:45 GMT /slideshow/bioluminescent-imaging-of-histidyltransfer-rna-synthetaseinduced-myositis-reveals-earlyphase-involvement-of-nfkbmediated-inflammation/51860205 young651@slideshare.net(young651) "Bioluminescent Imaging of Histidyl-Transfer RNA Synthetase-Induced Myositis Reveals Early-Phase Involvement of NF-kB-Mediated Inflammation" young651 My talk from the American College of Rheumatology Meeting in Boston, MA, November 14-19, 2014: • "Bioluminescent Imaging of Histidyl-Transfer RNA Synthetase-Induced Myositis Reveals Early-Phase Involvement of NF-kB-Mediated Inflammation". <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/11-7-2014presentation-final-edit-150820132945-lva1-app6891-thumbnail.jpg?width=120&height=120&fit=bounds" /> My talk from the American College of Rheumatology Meeting in Boston, MA, November 14-19, 2014: • "Bioluminescent Imaging of Histidyl-Transfer RNA Synthetase-Induced Myositis Reveals Early-Phase Involvement of NF-kB-Mediated Inflammation".

"Bioluminescent Imaging of Histidyl-Transfer RNA Synthetase-Induced Myositis Reveals Early-Phase Involvement of NF-kB-Mediated Inflammation" from Nicholas Young

]]> 554 8 https://cdn.slidesharecdn.com/ss_thumbnails/11-7-2014presentation-final-edit-150820132945-lva1-app6891-thumbnail.jpg?width=120&height=120&fit=bounds presentation 000000 http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 “Manocept, a derivative of FDA-approved 99mTc-Tilmanocept, exhibits diagnostic potential by specifically identifying macrophages in rheumatoid arthritis: a novel application of an existing drug” /slideshow/manocept-a-derivative-of-fdaapproved-99mtctilmanocept-exhibits-diagnostic-potential-by-specifically-identifying-macrophages-in-rheumatoid-arthritis-a-novel-application-of-an-existing-drug/51860068 6-2-2015tilmanocept-eularfinal-150820132606-lva1-app6892
My talk from The European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology meeting June 10-13, 2015 in Rome, Italy: • “Manocept, a derivative of FDA-approved 99mTc-Tilmanocept, exhibits diagnostic potential by specifically identifying macrophages in rheumatoid arthritis: a novel application of an existing drug”. Awarded a travel bursary to attend this conference. ]]>
My talk from The European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology meeting June 10-13, 2015 in Rome, Italy: • “Manocept, a derivative of FDA-approved 99mTc-Tilmanocept, exhibits diagnostic potential by specifically identifying macrophages in rheumatoid arthritis: a novel application of an existing drug”. Awarded a travel bursary to attend this conference. ]]> Thu, 20 Aug 2015 13:26:06 GMT /slideshow/manocept-a-derivative-of-fdaapproved-99mtctilmanocept-exhibits-diagnostic-potential-by-specifically-identifying-macrophages-in-rheumatoid-arthritis-a-novel-application-of-an-existing-drug/51860068 young651@slideshare.net(young651) “Manocept, a derivative of FDA-approved 99mTc-Tilmanocept, exhibits diagnostic potential by specifically identifying macrophages in rheumatoid arthritis: a novel application of an existing drug” young651 My talk from The European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology meeting June 10-13, 2015 in Rome, Italy: • “Manocept, a derivative of FDA-approved 99mTc-Tilmanocept, exhibits diagnostic potential by specifically identifying macrophages in rheumatoid arthritis: a novel application of an existing drug”. Awarded a travel bursary to attend this conference. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/6-2-2015tilmanocept-eularfinal-150820132606-lva1-app6892-thumbnail.jpg?width=120&height=120&fit=bounds" /> My talk from The European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology meeting June 10-13, 2015 in Rome, Italy: • “Manocept, a derivative of FDA-approved 99mTc-Tilmanocept, exhibits diagnostic potential by specifically identifying macrophages in rheumatoid arthritis: a novel application of an existing drug”. Awarded a travel bursary to attend this conference.

“Manocept, a derivative of FDA-approved 99mTc-Tilmanocept, exhibits diagnostic potential by specifically identifying macrophages in rheumatoid arthritis: a novel application of an existing drug” from Nicholas Young

]]> 820 11 https://cdn.slidesharecdn.com/ss_thumbnails/6-2-2015tilmanocept-eularfinal-150820132606-lva1-app6892-thumbnail.jpg?width=120&height=120&fit=bounds presentation 000000 http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 “Estrogen-mediated TLR8 expression via STAT1 facilitates endogenous miRokine ligand activation by exosomes containing miR-21: a novel innate inflammatory pathway in systemic lupus erythematosus” /slideshow/estrogenmediated-tlr8-expression-via-stat1-facilitates-endogenous-mirokine-ligand-activation-by-exosomes-containing-mir21-a-novel-innate-inflammatory-pathway-in-systemic-lupus-erythematosus/51859634 6-25-2015focismirokine-final-150820131647-lva1-app6891
My talk at The Federation of Clinical Immunology Societies (FOCIS) annual meeting June 24-27, 2015 in San Diego, CA: “Estrogen-mediated TLR8 expression via STAT1 facilitates endogenous miRokine ligand activation by exosomes containing miR-21: a novel innate inflammatory pathway in systemic lupus erythematosus”. Presented during the "Best in Rheumatology 2015" conference session. Recipient of a second consecutive travel award given to selected abstracts to attend this conference. ]]>
My talk at The Federation of Clinical Immunology Societies (FOCIS) annual meeting June 24-27, 2015 in San Diego, CA: “Estrogen-mediated TLR8 expression via STAT1 facilitates endogenous miRokine ligand activation by exosomes containing miR-21: a novel innate inflammatory pathway in systemic lupus erythematosus”. Presented during the "Best in Rheumatology 2015" conference session. Recipient of a second consecutive travel award given to selected abstracts to attend this conference. ]]> Thu, 20 Aug 2015 13:16:47 GMT /slideshow/estrogenmediated-tlr8-expression-via-stat1-facilitates-endogenous-mirokine-ligand-activation-by-exosomes-containing-mir21-a-novel-innate-inflammatory-pathway-in-systemic-lupus-erythematosus/51859634 young651@slideshare.net(young651) “Estrogen-mediated TLR8 expression via STAT1 facilitates endogenous miRokine ligand activation by exosomes containing miR-21: a novel innate inflammatory pathway in systemic lupus erythematosus” young651 My talk at The Federation of Clinical Immunology Societies (FOCIS) annual meeting June 24-27, 2015 in San Diego, CA: “Estrogen-mediated TLR8 expression via STAT1 facilitates endogenous miRokine ligand activation by exosomes containing miR-21: a novel innate inflammatory pathway in systemic lupus erythematosus”. Presented during the "Best in Rheumatology 2015" conference session. Recipient of a second consecutive travel award given to selected abstracts to attend this conference. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/6-25-2015focismirokine-final-150820131647-lva1-app6891-thumbnail.jpg?width=120&height=120&fit=bounds" /> My talk at The Federation of Clinical Immunology Societies (FOCIS) annual meeting June 24-27, 2015 in San Diego, CA: “Estrogen-mediated TLR8 expression via STAT1 facilitates endogenous miRokine ligand activation by exosomes containing miR-21: a novel innate inflammatory pathway in systemic lupus erythematosus”. Presented during the "Best in Rheumatology 2015" conference session. Recipient of a second consecutive travel award given to selected abstracts to attend this conference.

“Estrogen-mediated TLR8 expression via STAT1 facilitates endogenous miRokine ligand activation by exosomes containing miR-21: a novel innate inflammatory pathway in systemic lupus erythematosus” from Nicholas Young

]]> 642 9 https://cdn.slidesharecdn.com/ss_thumbnails/6-25-2015focismirokine-final-150820131647-lva1-app6891-thumbnail.jpg?width=120&height=120&fit=bounds presentation 000000 http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Nicholas Young, Sphingosine 1-phosphate Receptor Subtype Influence over Glioblastoma Multiforme Pathology /slideshow/30-minute-presentation-edit-final-775163/775163 30minutepresentationeditfinal-12272756077-phpapp01
My talk presenting my thesis work per invitation of Research and Development Division of Genzyme Corporation to the Lipid Storage Disorders Department. October 5, 2007. Boston, MA: "Sphingosine 1-phosphate Receptor Subtype Influence over Glioblastoma Multiforme Pathology". My PhD was earned through the Integrated Biomedical Sciences, September 2007, The Ohio State University, College of Medicine Columbus, OH. Area of focus for my PhD: Biochemical and Molecular Disease Mechanisms. Dissertation title: Sphingosine 1-phosphate Receptor Subtype Influence Over Glioblastoma Multiforme Malignant Behavior" ]]>
My talk presenting my thesis work per invitation of Research and Development Division of Genzyme Corporation to the Lipid Storage Disorders Department. October 5, 2007. Boston, MA: "Sphingosine 1-phosphate Receptor Subtype Influence over Glioblastoma Multiforme Pathology". My PhD was earned through the Integrated Biomedical Sciences, September 2007, The Ohio State University, College of Medicine Columbus, OH. Area of focus for my PhD: Biochemical and Molecular Disease Mechanisms. Dissertation title: Sphingosine 1-phosphate Receptor Subtype Influence Over Glioblastoma Multiforme Malignant Behavior" ]]> Fri, 21 Nov 2008 05:56:18 GMT /slideshow/30-minute-presentation-edit-final-775163/775163 young651@slideshare.net(young651) Nicholas Young, Sphingosine 1-phosphate Receptor Subtype Influence over Glioblastoma Multiforme Pathology young651 My talk presenting my thesis work per invitation of Research and Development Division of Genzyme Corporation to the Lipid Storage Disorders Department. October 5, 2007. Boston, MA: "Sphingosine 1-phosphate Receptor Subtype Influence over Glioblastoma Multiforme Pathology". My PhD was earned through the Integrated Biomedical Sciences, September 2007, The Ohio State University, College of Medicine Columbus, OH. Area of focus for my PhD: Biochemical and Molecular Disease Mechanisms. Dissertation title: Sphingosine 1-phosphate Receptor Subtype Influence Over Glioblastoma Multiforme Malignant Behavior" <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/30minutepresentationeditfinal-12272756077-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds" /> My talk presenting my thesis work per invitation of Research and Development Division of Genzyme Corporation to the Lipid Storage Disorders Department. October 5, 2007. Boston, MA: "Sphingosine 1-phosphate Receptor Subtype Influence over Glioblastoma Multiforme Pathology". My PhD was earned through the Integrated Biomedical Sciences, September 2007, The Ohio State University, College of Medicine Columbus, OH. Area of focus for my PhD: Biochemical and Molecular Disease Mechanisms. Dissertation title: Sphingosine 1-phosphate Receptor Subtype Influence Over Glioblastoma Multiforme Malignant Behavior"

Nicholas Young, Sphingosine 1-phosphate Receptor Subtype Influence over Glioblastoma Multiforme Pathology from Nicholas Young

]]> 1373 8 https://cdn.slidesharecdn.com/ss_thumbnails/30minutepresentationeditfinal-12272756077-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 https://cdn.slidesharecdn.com/profile-photo-young651-48x48.jpg?cb=1583154718 Throughout my career, I have developed experimental techniques to investigate scientific problems and develop whole organism solutions from a molecular level. My work in the field of brain cancer pathology trained me to think of the future therapeutic value of results and to direct my research toward developing animal models to treat this disease. After graduate school, I made the challenging transition from academia to industry. My industrial success is marked by high individual productivity as well as the creation of lab-wide initiatives and policies to increase overall output and efficiency. Currently, my research intends to provide insight into the gender-bias observed in autoimm... http://internalmedicine.osu.edu/rheumatology/research/ https://cdn.slidesharecdn.com/ss_thumbnails/n-170315155014-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/nicholas-young-cv-research-scientist-immunology-and-rheumatology/73179048 Nicholas Young, CV, re... https://cdn.slidesharecdn.com/ss_thumbnails/exercisepresentationsummaryedit-150820142357-lva1-app6892-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/stress-is-detrimental-and-moderate-exercise-is-beneficial-to-lupus-nephritis-pathogenesis-extramedicinal-influences-on-chronic-autoimmune-inflammation/51862564 "Stress is Detrimental... https://cdn.slidesharecdn.com/ss_thumbnails/curcumin-150820134219-lva1-app6891-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/oral-administration-of-nanoemulsion-curcumin-suppresses-lpsinduced-nfkb-signaling-in-inflammation-and-inhibits-macrophage-migration/51860637 "Oral administration o...